Get the Stockscreener App
33.53
0.47%
-0.16
After Hours:
33.53
Alkermes Plc stock is traded at $33.53, with a volume of 1.08M.
It is down -0.47% in the last 24 hours and down -1.50% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$33.69
Open:
$34.41
24h Volume:
1.08M
Relative Volume:
0.69
Market Cap:
$5.45B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
17.19
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-1.15%
1M Performance:
-1.50%
6M Performance:
+21.79%
1Y Performance:
+23.05%
1-Day Range:
$33.50
$34.45
1-Week Range:
$33.22
$35.41
52-Week Range:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
33.53 | 5.45B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - Marketscreener.com
What 5 Analyst Ratings Have To Say About Alkermes - Benzinga
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Liposomal Drug Delivery Market Detailed In New Research Report - openPR
First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq
Controlled Release Drug Delivery Market to Witness Massive - openPR
Alkermes price target raised to $35 from $34 at BofA - MSN
Where are the Opportunities in (ALKS) - Stock Traders Daily
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance
Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St
Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com
RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq
S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's
Alkermes initiated with a Sector Perform at RBC Capital - TipRanks
Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
RBC Capital sets Alkermes stock target at $40, sees growth potential - Investing.com UK
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa
Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Alkermes Plc to Host Earnings Call - ACCESS Newswire
Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World
Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily
What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World
Zacks Research Predicts Alkermes FY2027 Earnings - Defense World
UBS Group Upgrades Alkermes (NASDAQ:ALKS) to Neutral - MarketBeat
Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
UBS Upgrades Alkermes (ALKS) - Nasdaq
Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World
UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com
Alkermes upgraded to Neutral from Sell at UBS - TipRanks
Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
New York State Common Retirement Fund Increases Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Ieq Capital LLC Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes VP Samuel Parisi sells $65,892 in shares - Investing.com India
Alkermes VP Samuel Parisi sells $65,892 in shares By Investing.com - Investing.com UK
Illinois Municipal Retirement Fund Sells 11,878 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) is HealthInvest Partners AB's 10th Largest Position - MarketBeat
C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS) - MarketBeat
Todd Asset Management LLC Sells 30,957 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Sanctuary Advisors LLC Acquires 1,917 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Blue Trust Inc. Purchases 1,629 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.46%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):